Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers

The sodium glucose co‐transporter‐2 inhibitor dapagliflozin has been shown to decrease urinary albumin‐to‐creatinine ratio (UACR). This effect, however, varies among individual patients. In this study, we assessed the baseline characteristics and concurrent changes in other cardiovascular risk marke...

Descripción completa

Detalles Bibliográficos
Autores principales: Heerspink, Hiddo J. L., Sjöström, C. David, Inzucchi, Silvio E., Hallow, Melissa K., Cain, Valerie A., Rossing, Peter, Stefansson, Bergur V., Sartipy, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590413/
https://www.ncbi.nlm.nih.gov/pubmed/30414240
http://dx.doi.org/10.1111/dom.13579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590413/
https://www.ncbi.nlm.nih.gov/pubmed/30414240
http://dx.doi.org/10.1111/dom.13579

Ejemplares similares